DBV Technologies S.A. (ADR)
General ticker "DBVT" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $1.5B (TTM average)
DBV Technologies S.A. (ADR) does not follow the US Stock Market performance with the rate: -20.2%.
Estimated limits based on current volatility of 2.4%: low 8.73$, high 9.15$
Factors to consider:
- Earnings expected soon, date: 2026-10-28 bmo
- Total employees count: 125 as of 2025
- Top business risk factors: Inability to raise capital, Operating losses, Regulatory and compliance, Clinical trial failure, Supply chain disruptions
- Earnings for 6 months up through Q2 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [9.84$, 28.52$]
- 2026-12-31 to 2027-12-31 estimated range: [6.39$, 19.65$]
Financial Metrics affecting the DBVT estimates:
- Negative: with PPE of -5.9 at the end of fiscal year the price was very high
- Negative: negative Operating income
- Negative: negative Operating cash flow
- Negative: negative Net income
- Negative: negative Industry operating cash flow (median)
- Negative: 69.38 < Shareholder equity ratio, % of 72.21 <= 81.92
- Negative: negative Industry operating income (median)
- Negative: Investing cash flow per share per price, % of -0.08 <= 2.08
- Positive: Inventory ratio change, % of 0 <= 0
Short-term DBVT quotes
Long-term DBVT plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $15.73MM | $4.15MM | $0.00MM |
| Operating Expenses | $92.16MM | $120.74MM | $147.06MM |
| Operating Income | $-76.43MM | $-116.59MM | $-147.06MM |
| Non-Operating Income | $3.71MM | $2.73MM | $0.60MM |
| R&D Expense | $60.22MM | $89.90MM | $116.68MM |
| Income(Loss) | $-72.72MM | $-113.86MM | $-146.46MM |
| Taxes | $0.01MM | $0.06MM | $0.49MM |
| Net Income(Loss)* | $-72.73MM | $-113.92MM | $-146.95MM |
| Stockholders Equity | $140.19MM | $27.39MM | $168.77MM |
| Assets | $182.99MM | $65.66MM | $233.72MM |
| Operating Cash Flow | $-79.65MM | $-104.47MM | $-121.18MM |
| Capital expenditure | $0.68MM | $2.34MM | $0.53MM |
| Investing Cash Flow | $-0.81MM | $-0.76MM | $-1.37MM |
| Financing Cash Flow | $6.77MM | $0.59MM | $276.18MM |
| Earnings Per Share** | $-0.76 | $-1.18 | $-1.70 |
| Ordinary share to ADR | 1.00x | 1.00x | 1.00x |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.